Lana Moriarty joins ONC as director of consumer e-health

Laura Pedulli | | Health Exec | Precision Medicine

The Office of the National Coordinator for Health IT (ONC) has tapped Lana Moriarty to serve as its acting director for consumer e-health. Moriarty, who previously worked within the Health Resources and Services Administration, is replacing Lygeia Ricciardi, who left in July.

Before working at HRSA, Moriarty worked on gender issues at the World Bank and served as a Peace Corps volunteer.

“Lana’s commitment and impact on addressing gender issues while working with the World Bank and her connection to NHSC clinicians providing access to the nation’s underserved communities will help us here at ONC as we move forward with the goal of increasing consumer engagement and fostering stronger patient-provider partnerships,” said Kimberly Lynch, director of ONC’s Office of Programs & Engagement, in an email to ONC staff, according to Politico.

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.